Headache and cardiovascular disease: Old symptoms, new proposals

Future Cardiology

Volumn 6, Issue 5, 2010, Pages 703-723

  Providencia, Rui Andre ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

atrial septal aneurism; cardiac cephalgia; cardiovascular disease; coronary heart disease; headache; migraine; mitral valve prolapse; nitrates; patent foramen ovale; pulmonary arteriovenous malformations; stroke; sudden carotid artery dissection

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLYCERYL TRINITRATE; ILOPROST; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LISINOPRIL; NICORANDIL; NITROPRUSSIDE SODIUM; OLMESARTAN; PROSTACYCLIN; SILDENAFIL; TADALAFIL; THIAZIDE DIURETIC AGENT; UNIPROST; VARDENAFIL; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; AORTA COARCTATION; AORTA DISEASE; ARTERY DISSECTION; ATRIOVENTRICULAR BLOCK; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CLUSTER HEADACHE; COMORBIDITY; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HEART SEPTUM DEFECT; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MARFAN SYNDROME; MIGRAINE; MITRAL VALVE PROLAPSE; PATENT FORAMEN OVALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERIOVENOUS FISTULA; PULMONARY HYPERTENSION; RADIOFREQUENCY ABLATION; REVIEW; STEM CELL; STROKE; TENSION HEADACHE; TRANSIENT ISCHEMIC ATTACK; WEAKNESS;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FORAMEN OVALE, PATENT; HEADACHE; HEART ANEURYSM; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MIGRAINE DISORDERS; MITRAL VALVE INSUFFICIENCY; RISK FACTORS;

EID: 77958075491     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.76     Document Type: Review

References (229)

1. Janeway TC: A clinical study of hypertensive cardiovascular disease. Arch. Intern. Med. 12, 755-798 (1913). First evidence of a possible association between hypertension and headache.
2. Stewart McDG: Headache and hypertension. Lancet 1, 1261-1266 (1953). Interesting study showing that awareness of hypertension might lead patients to complain more frequently of headache.
3. Weiss NS: Relation of high blood pressure to headache, epistaxis and selected other symptoms. The United States Health Examination Survey of Adults. N. Engl. J. Med. 287(13), 631-633 (1972).
4. Pickering G: High Blood Pressure (2nd Edition). J.&A. Churchill Ltd, London, UK (1968).
5. Bulpitt CJ, Dollery CT, Carne S: Change in symptoms of hypertensive patients after referral to hospital clinic. Br. Heart. J. 38(2), 121-128 (1976).
6. Vandenburg MJ, Evans SJ, Kelly BJ, Bradshaw F, Currie WJ, Cooper WD: Factors affecting the reporting of symptoms by hypertensive patients. Br. Heart. J. 18(Suppl. 2), 189S-195S (1984).
7. Cooper WD, Glover DR, Hormbrey JM, Kimber GR: Headache and blood pressure: Evidence of a close relationship. J. Hum. Hypertens. 3(1), 41-44 (1989).
8. Cooper WD, Glover DR, Hormbrey JM: Symptoms in hypertensive patients: The effect of treatment withdrawal. J. Hypertens. Suppl. 6(4), S629-30 (1988).
9. Gus M, Fuchs FD, Pimentel M, Rosa D, Melo AG, Moreira LB: Behaviour of ambulatory blood pressure surrounding episodes of headache in mildly hypertensive patients. Arch. Int. Med. 161, 252-255 (2001).
10. Kruszewski P, Bieniaszewski L, Neubauer J, Krupa-Wokciechowska B: Headache in patients with mild to moderate hypertension is generally not associated with simultaneous blood pressure elevation. J. Hypertens. 18, 437-444 (2000).
11. Hansson L, Smith DH, Reeves R, Lapuerta P: Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch. Intern. Med. 160(11), 1654-1658 (2000).
12. Pickering TG: Effects of stress and behavioral interventions in hypertension-headache and hypertension: Something old, something new. J. Clin. Hypertens. 2(5), 345-347 (2000).
13. Fuchs FD, Gus M, Moreira LB, Moreira WD, Gonçalves SC, Nunes G: Headache is not more frequent among patients with moderate to severe hypertension. J. Hum. Hypertens. 17(11), 787-790 (2003).
14. Hagen K, Stovner LJ, Vatten L, Holmen J, Zwart JA, Bovim G: Blood pressure and risk of headache: A prospective study of 22,685 adults in Norway. J. Neurol. Neurosurg. Psychiatry. 72(4), 463-466 (2002).
15. Tronvik E, Stovner LJ, Hagen K, Holmen J, Zwart JA: High pulse pressure protects against headache: Prospective and cross-sectional data (HUNT study). Neurology. 70(16), 1329-1336 (2008).
16. Rosa C, Vignocchi G, Panattoni E, Rossi B, Ghione S: Relationship between increased blood pressure and hypoalgesia: Additional evidence for the existence of an abnormality of pain perception in arterial hypertension in humans. J. Hum. Hypertens. 8(2), 119-126 (1994).
17. Ghione S: Hypertension-associated hypalgesia. Evidence in experimental animals and humans, pathophysiological mechanisms, and potential clinical consequences. Hypertension 28(3), 494-504 (1996).
18. Headache Classification Subcommittee of the International Headache Society: The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl. 1), 9-160 (2004).
19. Hinchey J, Chaves C, Appignani B et al.: A reversible posterior leukoencephalopathy syndrome. N. Engl. J. Med. 334, 494-500 (1996).
20. Casey SO, Sampaio RC, Michel E, Truwit CL: Posterior reversible encephalopathy syndrome: Utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. Am. J. Neuroradiol. 21, 1199-1206 (2000).
21. Stott VL, Hurrel MA, Anderson TJ: Reversible posterior leukoencephalopathy syndrome: A mismoner reviewed. Intern. Med. J. 35, 83-90 (2005).
22. Cantillon P, Morgan M, Dundas R et al.: Patients' perceptions of changes in their blood pressure. J. Hum Hypertens. 11, 221-225 (1997).
23. Ferrari MD: Migraine. Lancet 351, 1043-1051 (1998).
24. Schwedt JT: The migraine association with cardiac anomalies, cardiovascular disease and stroke. Neurol. Clin. 27, 513-523 (2009).
25. Tietjen GE: Migraine as a systemic disorder. Neurology 68, 1555-1556 (1997).
26. Vanmolkot FH, Van Bortel LM, de Hoon JN: Altered arterial function in migraine of recent onset. Neurology 68, 1563-1570 (2007).
27. Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB: Migraine and cardiovascular disease: Possible mechanisms of interaction. Neurology 72(21), 1864-1871 (2009).
28. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ: Cardiovascular risk factors and migraine: The GEM population-based study. Neurology 64(4), 614-620 (2005).
29. Ford ES, Li C, Pearson WS, Zhao G, Strine TW, Mokdad AH: Body mass index and headaches: Findings from a national sample of US adults. Cephalalgia 28(12), 1270-1276 (2008).
30. Bigal ME, Kurth T, Santanello N et al.: Migraine and cardiovascular disease: A population-based study. Neurology 74(8), 628-635 (2010).
31. Wiehe M, Fuchs SC, Moreira LB, Moraies RS, Fuchs FD: Migraine is more frequent in individuals with optimal and normal blood pressure: A population-based study. J. Hypertens. 20(7), 1303-1306 (2002).
32. Schürks M, Buring JE, Kurth T: Migraine, migraine features, and cardiovascular disease. Headache 50(6), 1031-1040 (2010).
33. Bousser MG, Welch KA: Relation between migraine and stroke. Lancet Neurol. 4, 533-542 (2005).
34. Féré C: Note sur un cas de migraine ophtalmique à accès répétés suivis de mort. Rev. Med. (Paris) 3, 194-201 (1883).
35. Broderik JP, Swanson JW: Migraine-related strokes: Clinical profile and prognosis in 20 patients. Arch. Neurol. 44, 868-871 (1987).
36. Arboix A, Massons J, García-Eroles L, Oliveres M, Balcells M, Targa C: Migrainous cerebral infarction in the Sagrat Cor Hospital of Barcelona stroke registry. Cephalalgia 23(5), 389-394 (2003).
37. Kruit MC, van Buchem MA, Hofman PAM et al.: Migraine as a risk factor for subclinical brain lesions. JAMA 291(4), 427-434 (2004).
38. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA: Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128, 2068-2077 (2005).
39. Swartz R, Kern R: Migraine is associated with MRI white matter abnormalities: A meta-analysis. Arch. Neurol. 61, 1366-1368 (2004).
40. Scher AI, Gudmundsson LS, Sigurdsson S et al.: Migraine headache in middle age and late-life brain infarcts. JAMA 391(24), 2563-2570 (2009).
41. Etminan M, Takkouche B, Isorna FC, Samii A: Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ 330(7482), 63 (2005). Meta-analysis with evidence for a positive association between migraine with aura and stroke.
42. Kurth T, Gaziano M, Cook NR et al.: Migraine and risk of cardiovascular disease in men. Arch. Intern. Med. 167, 795-801 (2007). (Pubitemid 46658337)
43. Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE: Migraine, vascular risk, and cardiovascular events in women: Prospective cohort study. BMJ. 337, a636 (2008).
44. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T: Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ 339, b3914 (2009).
45. Takano T, Tian GF, Peng W et al.: Cortical spreading depression causes and coincides with tissue hypoxia. Nat. Neurosci. 10, 754-762 (2007).
46. Dalkara T, Nozari A, Moskowitz MA: Migraine aura pathophysiology: The role of blood vessels and microembolisation. Lancet Neurol. 9(3), 309-317 (2010).
47. Bousser MG: Estrogens, migraine and stroke. Stroke 35, 2652-2656 (2004).
48. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM: Severe vascular events in migraine patients. Headache 44(7), 642-651 (2004).
49. Hall GC, Brown MM, Mo J, MacRae KD: Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology 62(4), 563-568 (2004).
50. Dodick D, Lipton RB, Martin V et al.: Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(5), 414-425 (2004).
51. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome. Ann. Neurol. 16(4), 481-488 (1984).
52. Tournier-Lasserve E, Iba-Zizen MT, Romero N, Bousser MG: Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 22(10), 1297-1302 (1991).
53. Rose KM, Carson AP, Sanford CP et al.: Migraine and other headaches: Associations with rose angina and coronary heart disease. Neurology 63, 2233-2239 (2004).
54. Sternfeld B, Stang P, Sidney S: Relationship of migriane headaches to experience of chest pain and subsequent risk for myocardial infaction. Neurology 45, 2135-2142 (1995).
55. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE: Migraine and risk of cardiovascular disease in women. JAMA 296(3), 283-291 (2006).
56. O'Keefe ST, Tsapatsaris NP, Beetham WP: Increased prevalence of migraine and chest pain in patients with primary Raynaud's disease. Ann. Intern. Med.116, 985-989 (1992).
57. Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Theroux P: Is variant angina the coronary manifestation of a generalized vasospastic disorder? N. Engl. J. Med. 302, 763-766 (1981).
58. Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin. Proc. 59(1), 17-20 (1984).
59. Di Tullio MR: Patent foramen ovale: Echocardiographic detection and clinical relevance in stroke. J. Am. Soc. Echocardiogr. 23, 144-155 (2010).
60. Lechat P, Mas JL, Lascault G et al.: Prevalence of patent foramen ovale in patients with stroke. N. Engl. J. Med. 318(18), 1148-1152 (1988). First evidence of an increased prevalence of patent foramen ovale (PFO) in patients with stroke.
61. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann. Intern. Med. 117, 461-465 (1992).
62. Handke M, Harloff A, Oschenwski M, Hetzel A, Geibel A: Patent foramen ovale and cryptogenic stroke in older patients. N. Engl. J. Med. 357, 2262-2268 (2007).
63. Meissner I, Khandheria BK, Heit JA et al.: Patent foramen ovale: Inocent or guilty? evidence from a prospective population-based study. J. Am. Coll. Cardiol. 47(2), 440-445 (2006).
64. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S: Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J. Am. Coll. Cardiol. 49, 797-802 (2007).
65. Alsheikh-Ali AA, Thaler DE, Kent DM: Patent foramen ovale in cryptogenic stroke: Incidental or pathogenic? Stroke 40, 2349-2355 (2009).
66. Thompson T, Evans W: Paradoxical embolism. Q. J. Med. 23, 135-150 (1930).
67. Falk V, Walther T, Krankenberg H, Mohr FW: Trapped thrombus in a patent foramen ovale. Thorac. Cardiovasc. Surg. 45, 90-92 (1997).
68. Beacock DJ, Watt VB, Oakley GD, Al Mohammed A: Paradoxical embolism with a patent foramen ovale and atrial septal aneurysm. Eur. J. Echocardiogr. 7(2), 171-174 (2006).
69. Webster MW, Chancellor AM, Smith HJ et al.: Patent foramen ovale in young stroke patients. Lancet 2, 11-12 (1998)
70. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li MG, Mohr JP: Characteristics of patent foramen ovale assocaited with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke 25, 582-586 (1994).
71. Hausmann D, Mugge A, Daniel WG: Identification of patent foramen ovale permitting paradoxic embolism. J. Am. Coll. Cardiol. 26, 1030-1038 (1995).
72. Overel JR, Boni E, Lees KR: Interartrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 55(8), 1172-1179 (2000). Proof that when a PFO is associated with an atrial septal aneurysm, the risk of ischemic stroke is higher.
73. Giardini A, Donti A, Formigari R et al.: Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. Int. J. Cardiol. 120(3), 357-362 (2007).
74. Strotmann JM, Voelker W, Schanzenbaecher P: Persistence of the eustachian valve in secundum atrial septal defects: Possible implications for cerebral embolism and transcatheter closure procedures. Heart 86(1), E5 (2001).
75. Rigatelli G, Dell'Avvocata F, Giordan M et al.: Embolic implications of combined risk factors in patients with patent foramen ovale (the CARPE criteria): Consideration for primary prevention closure? J. Interv. Cardiol. 22(4), 398-403 (2009).
76. Mas J-L, Arquizan C, Lamy C et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med. 345, 1740-1746 (2001).
77. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP: Effect of medical tratment in stroke patients with patent foramen ovale: Patent foramen ovale in cryptogenic stroke study. Circulation 105, 2625-2631 (2002).
78. Mas JL, Zuber M: Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm or both and cryptogenic stroke or transient ischemic attack. french study group on patent foramen ovale and atrial septal aneurysm. Am. Heart J. 130, 1083-1088 (1995).
79. Cujec B, Mainra R, Johnson DH: Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can. J. Cardiol. 15, 57-64 (1999).
80. Di Tullio MR, Homma S: Patent foramen ovale and stroke: What should be done? Curr. Opin. Hematol. 16(5), 391-396 (2009)
81. O'Gara PT, Messe SR, Tuzcu EM et al.: Percutaneous device closure of patent foramen ovale for secondary stroke prevention: A call for completion of randomized clinical trials. A science advisory from the american heart association/ american stroke association and the american college of cardiology foundation. J. Am. Coll. Cardiol. 53(21), 2014-2018 (2009).
82. NMT Medical: NMT Medical announces preliminary results of CLOSURE I PFO/stroke trial [press release]. June 17 (2010)
83. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL: Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356(9242), 1648-1651 (2000). One of the first papers regarding the migraine-PFO connection.
84. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E: Transcatheter closure of patent foramen ovale: A new migraine treatment? J. Interv. Cardiol. 16(1), 39-42 (2003).
85. Post MC, Thijs V, Herroelen L, Budts WI: Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 62(8), 1439-1440 (2004).
86. Reisman M, Christofferson RD, Jesurum J et al.: Migraine headache relief after transcatheter closure of patent foramen ovale. J. Am. Coll. Cardiol. 45(4), 493-495 (2005).
87. Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J: Patent foramen ovale, a possible cause of symptomatic migraine: A study of 74 patients with acute ischemic stroke. Cerebrovasc. Dis. 13(2), 102-106 (2002).
88. Schwedt TJ, Dodick DW: Patent foramen ovale and migraine-bringing closure to the subject. Headache 46(4), 663-671 (2006).
89. Carod-Artal FJ, da Silveira Ribeiro L, Braga H, Kummer W, Mesquita HM, Vargas AP: Prevalence of patent foramen ovale in migraine patients with and without aura compared with stroke patients. A transcranial Doppler study. Cephalalgia 26(8), 934-939 (2006).
90. Dalla Volta G, Guindani M, Zavarise P, Griffini S, Pezzini A, Padovani A: Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J. Headache Pain 6(4), 328-330 (2005).
91. Moaref AR, Petramfar P, Aghasaedehi K et al.: Patent foramen ovale in patients with tension headache: Is it as common as in migraineurs? An age- and sex-matched comparative study. J. Headache Pain 10(6), 431-434 (2009).
92. Schwedt TH, Demaerschalk BM, Dodick DW: Patent foramen ovale and migraine: A quantitative systematic review. Cephalalgia 28, 531-540 (2008).
93. Schwerzmann M, Nedeltchev K, Lagger F et al.: Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 65(9), 1415-1418 (2005)
94. Anzola GP, Morandi E, Casilli F, Onorato E: Different degrees of right-to-left shunting predict migraine and stroke: Data from 420 patients. Neurology 66(5), 765-767 (2006).
95. Jesurum JT, Fuller CJ, Velez CA et al.: Migraineurs with patent foramen ovale have larger right-to-left shunt despite similar atrial septal characteristics. J. Headache Pain 8(4), 209-216 (2007).
96. Rigatelli G, Dell'avvocata F, Cardaioli P et al.: Migraine-patent foramen ovale connection: Role of prominent eutachian valve and large chiari network in migrainous patients. Am. J. Med. Sci. 336(6), 458-461 (2008).
97. Anzola GP, Frisoni GB, Morandi E, Casilli F, Onorato E: Shunt-associated migraine responds favorably to atrial septal repair: A case-control study. Stroke 37(2), 430-434 (2006).
98. Dowson A, Mullen MJ, Peatfield R et al.: Migraine intervention with starflex technology (MIST) trial: A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117(11), 1397-1404 (2008). Landmark study that failed to show any benefit of PFO closure in migraine resolution.
99. Johansson MC, Dellborg M, Eriksson P: Letter by Johansson et al regarding article, "Migraine Intervention With STARFlex Technology (MIST) trial". Circulation 119(5), e193 (2009).
100. Rundek T, Elkind MS, Tullio MR et al.: Patent foramen ovale and migraine: A cross-sectional study from the northern manattan study (NOMAS). Circulation 118, 1419-1424 (2008).
101. Rigatelli G, Cardaioli P, Dell'Avvocata F et al.: Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design. Cardiovasc. Revasc. Med. 11(1), 29-33 (2010).
102. Rigatelli G, Dell'Avvocata F, Ronco F et al.: Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism. JACC Cardiovasc. Interv. 3(3), 282-287 (2010).
103. Rigatelli G, Cardaioli P, Giordan M et al.: Transcatheter interatrial shunt closure as a cure for migraine: Can it be justified by paradoxical embolism-risk-driven criteria? Am. J. Med. Sci. 337(3), 179-181 (2009).
104. Wahl A, Praz F, Findling O et al.: Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. Catheter. Cardiovasc. Interv. 74(1), 124-129 (2009).
105. Tepper SJ, Cleves C, Taylor FR: Patent foramen ovale and migraine: Association, causation and implications of clinical trials. Curr. Pain. Headache. Rep. 13(3), 221-226 (2009).
106. Rodés-Cabau J, Mineau S, Marrero A et al.: Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale. Am. J. Cardiol. 101(5), 688-692 (2008). Important study regarding new onset of migraine with aura after percutaneous closure of atrial septal defects.
107. Wilmshurst P, Nightingale S: The role of cardiac and pulmonary pathology in migraine: A hypothesis. Headache 46(3), 429-434 (2006). Proposed mechanisms for the cardiac shunt-migraine connection.
108. Nozari A, Dilekoz E, Sukhotinsky I et al.: Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann. Neurol. 67(2), 221-229 (2010).
109. Wilmshurst P, Nightingale S: Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin. Sci. 100, 215-220 (2001). More on the pathophysiology of cardiac shunt-migraine connection. (Pubitemid 32165366)
110. Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL: Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart 90(11), 1315-1320 (2004).
111. Koseoglu E, Yazar S, Koc I: Is Toxoplasma gondii a causal agent in migraine? Am. J. Med. Sci. 338(2), 120-122 (2009).
112. Prandota J: Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation. Int. J. Neurosci. 120(2), 81-87 (2010).
113. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W: The influence of percutaneous closure of atrial septal defects device closure on the occurrence of migraine. Eur. Heart. J. 26, 1533-1537 (2005).
114. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R: Association of interatrial shunts and migraine headaches: Impact of transcatheter closure. J. Am. Coll. Cardiol. 45(4), 489-492 (2005).
115. Providencia R, Silva CS, Costa MP, Quintal NP, Luzeiro IM, Leitao-Marques AM: Is there any relation between echocardiographic patterns of atrial septal defect (ASD) and migraine? Eur. J. Anesthesiol. 25(Suppl. 43), 32 (2008).
116. Luermans JG, Post MC, Temmerman F et al.: Is a predominant left-to-right shunt associated with migraine? A prospective atrial septal defect closure study. Catheter. Cardiovasc. Interv. 74(7), 1078-1084 (2009).
117. Rodés-Cabau J, Molina C, Serrano-Munuera C et al.: Migraine symptoms related to the percutaneous closure of an atrial septal defect. Catheter. Cardiovasc. Interv. 60, 540-542 (2003).
118. Sharifi M, Dehghani M, Mehdipour M, Al-Bustami O, Emrani F, Burks J: Intense migraines secondary to percutaneous closure of atrial septal defects. J. Interv. Cardiol. 18, 181-183 (2005).
119. Fernández-Mayoralas DM, Fernández-Jaen A, Munoz-Jareo N, Gutiérrez-Larraya F, Calleja-Pérez B, San Antonio Arce V: Migraine symptoms related to the percutaneous closure of an ostium secundum septal defect: Report of four paediatric cases and review of the literature. Cephalalgia 27, 550-556 (2007).
120. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL: Clopidogre reduces migraine with aura after transcatehter closure of persistente foramen ovale and atrial septal defects. Heart 91, 1173-1175 (2005).
121. Providencia R, Silva CS, Costa MP, Quintal NP, Luzeiro IM, Leitao-Marques AM: Can the short aortic rim be a risk factor for developing migraine after percutaneous closure of secundum-type atrial septal defects? Eur. J. Anesthesiol. 25(Suppl. 43), 32 (2008).
122. Quaresma A, Lopes P, Quintal I et al.: Encerramento da comunicaçao interauricular: Um novo tratamento para a migraine? Rev. Port. Cardiol. 28(Suppl. 1), 94 (2009).
123. Olivares-Reyes A, Chan S, Lazar EJ, Bandlamudi K, Narla V, Ong K: Atrial septal aneurysm: A new classification in two hundred five adults. J. Am. Soc. Echocardiogr. 10(6), 644-656 (1997).
124. Serafini O, Misuraca G, Siniscalchi A et al.: Prevalence of aneurysm of the interatrial septum in the general population and in patients with a recent episode of cryptogenetic ischemic stroke: A tissue harmonic imaging transthoracic echocardiography study in 5,631 patients. Monaldi. Arch. Chest. Dis. 66(4), 264-269 (2006).
125. Di Tullio MR: Patent foramen ovale: Endiographic detection and clinical relevance in stroke. J. Am. Soc. Echocardiogr. 23, 144-155 (2010).
126. Mügge A, Daniel WG, Angermann C et al.: Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation 91, 2785-2792 (1995).
127. Zhao BW, Mizushige K, Xian TC, Matsuo H: Incidence and clinical significance of interatrial shunting in patients with atrial septal aneurysm detected by contrast transesophageal echocardiography. Angiology 50(9), 745-753 (1999).
128. Mattioli AV, Aquilina M, Oldani A, Longhini C, Mattioli G: Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur. Heart. J. 22(3), 261-268 (2001).
129. Guntheroth WG, Schwaegler R, Trent E: Comparative roles of the atrial septal aneurysm versus patent foramen ovale in systemic embolization with inferences from neonatal studies. Am. J. Cardiol. 94(10), 1341-1343 (2004).
130. Rigatelli G, Aggio S, Cardaioli P et al.: Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: An alternative concurrent mechanism for arterial embolism? JACC Cardiovasc. Interv. 2(7), 655-662 (2009).
131. Overel JR, Boni E, Lees KR: Interartrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 55(8), 1172-1179 (2000).
132. Carerj S, Narbone MC, Zito C et al.: Prevalence of atrial septal aneurysm of the interatrial spetum in the general population and in patients with a recent episode of cryptogenic ischemic stroke: An echocardiographic study. Headache 43(7), 725-728 (2003).
133. Martín Balbuena S, Fuentes B, Lara M et al.: Migraine as predictive factor of the presence of atrial setum aneurysm in patients with stroke and patent foramen ovale. Neurologia. 24(3), 160-164 (2009).
134. Chilukuri K, Sinha S, Berger R et al.: Association of transseptal puncutres with isolated migraine aura in patients undergoing catheter ablation of cardiac arrhytmias. J. Cardiovasc. Electrophysiol. 20(11), 1227-1230 (2009).
135. Saravanan P, Lang C, Davidson N: Migraine following trans-septal access for catheter ablation of cardiac arrhythmias. Headache 49(7), 1065-1067 (2009).
136. Rogan MP, Walsh KP, Gaine SP: Migraine with aura following atrial septostomy for pulmonary arterial hypertension. Nat. Clin. Pract. Cardiovasc. Med. 4(1), 55-58 (2007).
137. Thenganatt J, Schneiderman J, Hyland RH, Edmeads J, Mandzia JL, Faughnan ME: Migraines linked to intrapulmonary right-to-left shunt. Headache 46(3), 439-443 (2006).
138. Post MC, Thijs V, Schonewille WJ et al.: Embolization of pulmonary arterioveous malformations and decrease in prevalence of migriane. Neurology 66(2), 202-205 (2006).
139. Post MC, van Gent MW, Mager JJ, Schonewille WJ, Plokker HW, Westermann CH: Pulmonary arteriovenous malformations and migraine: A new vision. Respiration 76(2), 228-233 (2008).
140. Marziniak M, Jung A, Guralnik V, Evers S, Prudlo J, Geisthoff UW: An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Cephalalgia 29(1), 76-81 (2009).
141. Truong T, Slavin L, Kashani R et al.: Prevalence of migraine headaches in patients with congenital heart disease. Am. J. Cardiol. 101(3), 396-400 (2008).
142. Barnett HJ, Jones MW, Boughner DR, Kostuk WJ: Cerebral ischemic events associated with prolapsing mitral valve. Arch. Neurol. 33, 777-782 (1976).
143. Amat G, Louis PJ, Loisy C, Centonze V, Pelage S: Migraine and the mitral valve prolapse syndrome. Adv. Neurol. 33, 27-29 (1982).
144. Spence JD, Wong DG, Melendez LJ, Nichol PM, Brown JD: Increased prevalence of mitral valve prolapse in patients with migraine. Can. Med. Assoc. J. 131, 1457-1460 (1984).
145. Litman GI, Friedman HM: Migraine and the mitral valve prolapse syndrome. Am. Heart. J. 96, 610-614 (1978).
146. Gamberini G, D'Alessandro R, Labriola E et al.: Further evidence on the association of mitral valve prolapse and migraine. Headache 24(1), 39-40 (1984).
147. Termine C, Trotti R, Ondei P et al.: Mitral valve prolapse and abnormalities of haemostatis in children and adolescents with migraine with aura and other idiopathic headaches: A pilot study. Acta. Neurol. Scand. 122(2), 91-96 (2010).
148. Kostuk WJ, Boughner DR, Barnett HM, Silver MD: Strokes a complication of mitral-leaflet prolapse? Lancet 2, 313-316 (1977).
149. Borin C, Troost E, Thijs V, Moons P, Budts W: Migraine and coarctation of the aorta: Prevalence and risk factors. Acta. Cardiol. 63(4), 431-435 (2008).
150. Shahar E, Borenstein A, Filk D: Severe migraine associated with oarctation of aorta: Complete recovery following balloon dilation. J. Child. Neurol. 15(12), 826-827 (2000).
151. Staals JE, Braun KP, van Loo-Maurus KE, Vles JS: Stenting for coarctation of the aorta precipitating migraine with aura. J. Child. Neurol. 22(3), 321-323 (2007).
152. Knudsen S, Russel MB: Increased risk of migraine in Marfan's syndrome. Acta. Neurol. Scand. 114(4), 281-286 (2006).
153. Knudson S, Fukutake T, Sakakibara R, Mori M, Araki M, Hattori T: Chronic intractable headache in a patient with Marfan's syndrome. Headache 37(5), 291-295 (1997).
154. Vis JC, Timmermans J, Post MC et al.: Increased prevalence of migraine in marfan syndrome. Int. J. Cardiol. 136(3), 330-334 (2009).
155. Mirza Z, Hayward P, Hulbert D: Spontaneous carotid artery dissection presenting as migraine - a diagnosis not to be missed. J. Accid. Emerg. Med. 15, 187-199 (1998).
156. Schievnik WI, Mokri B, Piepgras DG: Spontaneous dissection of the cervicocephalic arteries in childhood and adolescence. Neurology 44, 1607-1612 (1994).
157. Ganesan V, Kirkham FJ: Carotid dissection causing stroke in a child with migraine. BMJ 314, 291-292 (1997).
158. Mokri B, Sundt TM Jr, Houser OW: Spontaneous internal carotid dissection, hemicrania and hoerner's syndrome. Arch. Neurol. 36(11), 677-680 (1979).
159. Laing C, Thomas DJ, Mathias CJ, Unwin RJ: Headache, hypertension and horner's syndrome. J. R. Soc. Med. 93, 535-536 (2000).
160. Leys D, Lucas C, Gobert M, Deklunder G, Pruvo JP: Cervical artery dissections. Eur. Neurol. 37(1), 3-12 (1997).
161. Neau JP, Petit E, Gil R: Dissection of cervical arteries. Presse. Med. 30(38), 1882-1889 (2001).
162. Georgiadis D, Arnold M, von Buedingen HC, et al.: Aspirine vs anticoagulation in carotid artery dissection: A study of 298 patients. Neurology 72(21), 1810-1815 (2009).
163. Van Damme H, Martin D, Stassen MP, Limet R: Spontaneous dissection of the internal carotid artery. apropos of 7 cases and a review of the literature. J. Mal. Vasc. 15(1), 14-22 (1990).
164. Mokri B, Sundt TM Jr, Houser OW, Pipegras DG: Spontaneous dissection of the cervical internal carotid artery. Ann. Neurol. 19, 126-138 (1986).
165. Stöllberger C, Finsterer J, Fousek C, Waldenberger FR, Haumer H, Lorenz W: Headache as the initial manifestation of acute aortic dissection type A. Cephalalgia 18(8), 583-584 (1998).
166. Mathys J, Lachat M, Herren T: Headache as a manifestation of a life-threatening vascular disorder. Headache 44(7), 706-709 (2004).
167. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P: Causal relationship of susceptibility genes to ischemic stroke: Comparison to ischemic heart disease and biochemical determinants. PLoS One 5(2), e9136 (2010).
168. Schürks M, Rist PM, Kurth T: MTHFR 677C>T and ACE D/I polymorphisms in migraine: A systematic review and meta-analysis. Headache 50(4), 588-599 (2010).
169. Schürks M, Zee RYL, Buring JE, Kurth T: ACE D/I polymorphism, migraine, and cardiovascular disease in women. Neurology 72, 650-656 (2009).
170. Schürks M, Zee RYL, Buring JE, Kurth T: Interrelationships between the MTHFR 677C>T polymorphism, migraine and cardiovascular disease. Neurology 71(7), 505-513 (2008).
171. Hill JM, Zalos G, Halcox JP et al.: Circulating endotelhial progenitor cells, vascular function and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
172. Vasa M, Fichtlscherer S, Aicher A et al.: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89, E1-E7 (2001).
173. Ghani U, Shuaib A, Salam A et al.: Endothelial progenitor cells during cerebrovascular disease. Stroke 26, 151-153 (2005).
174. Kunz GA, Liang G, Cuculi F et al.: Circulating endothelial progenitor cells predict coronary artery disease severity. Am. Heart. J. 152, 190-195 (2006).
175. Werner N, Kosiol S, Schiegl T et al.: Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005). (Pubitemid 41262334)
176. Schmidt-Lucke C, Rössig L, Fichtlscherer S et al.: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endovenous vascular repair. Circulation 111, 2981-2987 (2005).
177. Lee ST, Chu K, Jung KH et al.: Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 70, 1510-1517 (2008).
178. Matharu M, Goadsby P: Cluster headache update on a common neurological problem. Practical Neurology 1, 42-49 (2001).
179. Loder E: Cluster headache and the heart. Curr. Pain. Headache. Rep. 10(2), 142-146 (2006).
180. Ryssekk DM, von der Lippe A: Cluster headache: Heart rate and blood pressure changes during spontaneous attacks. Cephalalgia 2(2), 61-70 (1982).
181. Kruzewski P, Bordini C, Brubakk AO, Sjaastad O: Cluster headache: Alterations in heart rate, blood pressure and orthostatic responses during spontaneous attacks. Cephalalgia 12(3), 172-177 (1992).
182. Kruszewski P, Bordini C, Brubakk AO, Sjaastad O: Cluster headache: Cardiovascular responses to head-up tilt. Headache 35(8), 465-469 (1995).
183. van Vliet JA, Vein AA, Ferrari MD, van Disk JG: Cardiovascular autonomic function tests in cluster headache. Cephalalgia 26(3), 329-331 (2006).
184. Dalla Volta G, Guidani M, Zavarise P, Griffini S, Pezzini A, Padovani A: Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J. Headache Pain 6(4), 328-330 (2005).
185. Finocchi C, Del Sette M, Angeli S, Rizzi D, Gandolfo C: Cluster headache and right-to-left Shunt on contrast transcranial doppler: A case-control Study. Neurology 63(7), 1309-1310 (2004).
186. Lipton RB, Lowenkopf T, Bajwa ZH et al.: Cardiac cephalgia: A treatable form of exertional headache. Neurology 49, 813-816 (1997). Paper proposing cardiac cephalgia as a separate entity associated to coronary heart disease.
187. Bini A, Evangelista A, Castelini P et al.: Cardiac Cephalgia. J. Headache Pain 10, 3-9 (2009).
188. Bowen J, Oppenheimer G: Headache as presentation of angina: Reproduction of symptoms during angioplasty. Headache 33, 238-239 (1999).
189. Ishida A, Sunagawa O, Touma T, Shinzato Y, Kawazoe N, Jukiyama K: Headache as a manifestation of myocardial infarction. Jpn Heart. J. 37, 261-263 (1996).
190. Chen SP, Fuh JL, Yu WC, Wang SJ: Cardiac cephalalgia. Case report and review of the literature with new ICHD-II criteria revisited. Eur. Neurol. 51(4), 221-226 (2004).
191. Grace A, Horgan J, Breathnach K, Staunton H: Anginal headache and its basis. Cephalalgia. 17, 195-196 (1997).
192. Meller ST, Gebhart GF: A critical review of the afferent pathways and the potential chemical mediatores involved in cardiac pain. Neuroscience 48, 501-524 (1992).
193. Silbert PL, Hankey GJ, Prentice DA: Angiographically demonstrated arterial spasm in a case of benignal sexual headache and benign exertional headache. Aust. N. Z. J. Med. 19, 466-468 (1989).
194. Morlote JG, Garcia JMF, Fernández JJT, Catedral ML, Rodríguez ER, Gömez JP: Cardiac cephalgia: An underdiagnosed condition? Rev. Esp. Cardiol. 58(12), 1476-1478 (2005).
195. Rambihar VS: Headache angina. Lancet 357, 72 (2001).
196. Auer J, Berent R, Lassnig E, Eber B: Headache as a manifestation of fatal myocardial infarction. Neurol. Sci. 22, 395-397 (2001).
197. Famularo G, Polchi S, Tarroni P: Headache as a presenting symptom of acute myocardial infarction. Headache 42, 1025-1028 (2002).
198. Brunton TL: Use of nitrate of amyl in angina pectoris. Lancet 2, 628-629 (1867).
199. Thadani U, Rodgers T: Side effects of using nitrates to treat angina. Expert Opin. Drug. Saf. 5(5), 667-674 (2006).
200. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P: Vasodilators in the management of acute heart failure. Crit. Care. Med. 36(Suppl. 1), S95-105 (2008).
201. Thadani U, Rodgers T: Side effects of using nitrates to treat angina. Expert Opin. Drug Saf. 5(5), 667-674 (2006).
202. Juhász G, Zsombök T, Gonda X, Bagdy G: Nitroglycerin-induced headaches. Orv. Hetil. 145(46), 2323-2328 (2004).
203. Bagdy G, Riba P, Kecskeméti V, Chase D, Juhász G: Headache-type adverse effects of NO donors: Vasodilation and beyond. Br. J. Pharmacol. 160(1), 20-35 (2010).
204. Iversen HK: Experimental headache in humans. Cephalalgia 15, 281-287 (1995).
205. Ekbom K, Sjöstrand C, Svensson DA, Waldenlind E: Periods of cluster headache induced by nitrate therapy and spontaneous remission of angina pectoris during active clusters. Cephalalgia 24(2), 92-98 (2004).
206. Markham A, Plosker GL, Goa KL: Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 60(4), 955-974 (2000).
207. Evans RW: Sildenafil can trigger cluster headaches. Headache 46(1), 173-174 (2006).
208. Moore RA, Derry S, McQuay HJ: Indirect comparison of interventions using published randomised trials: Systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol. 5, 18 (2005).
209. Wienecke T, Olesen J, Oturai PS, Ashina M: Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139(1), 106-116 (2008).
210. Gryglewski RJ: Prostacyclin among prostanoids. Pharmacol. Rep. 60(1), 3-11 (2008).
211. ESPS Group: European Stroke Prevention study. Stroke 21(8), 1122-1130 (1990)
212. Fox K, Garcia MA, Ardissino D et al.: Guidelines on the management of stable angina pectoris. Executive summary: The task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart. J. 27(11), 1341-1381 (2006). (Pubitemid 43998110)
213. Meyers AM, Topham L, Ballow J, Totah D, Wilke R: Adverse reactions to dipyridamole in patients undergoing stress/rest cardiac perfusion testing. J. Nucl. Med. Technol. 30(1), 21-24 (2002).
214. Lindgren A, Husted S, Staaf G, Ziegler B: Dipyridamole and headache - a pilot study of initial dose titration. J. Neurol. Sci. 223(2), 179-184 (2004).
215. Lökk J: Dipyridamole-associated headache in stroke patients - interindividual differences? Eur. Neurol. 62(2), 109-113 (2009).
216. Theis JG, Deichsel G, Marshall S: Rapid development of tolerance to dipyridamole-associated headaches. Br. Heart. J. 48(5), 750-755 (1999).
217. European Stroke Prevention Study 2: Efficacy and safety data. J. Neurol. Sci. 151(Suppl.), S1-S77 (1997).
218. Law MR, Morris JK, Wald NJ: Calcium channel blockers and headache. Br. Heart. J. 63(2), 157-158 (2007).
219. Law M, Morris JK, Jordan R, Wald N: Headaches and the treatment of blood pressure. results from a meta-analysis of 94 randomized placebo-controlled trials with 24000 participants. Circulation 112, 2301-2306 (2005).
220. Bussone G, Leone M, Peccarisi C et al.: Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 30, 411-417 (1990).
221. Leone M, D'Amico D, Frediani F et al.: Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo. Neurology 1382-1385, (2000).
222. Cohen AS, Matharu MS, Goadsby PJ: Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 69, 668-675 (2007).
223. Leroux E, Ducros A: Cluster headache. Orphanet. J. Rare. Dis. 3, 20 (2008).
224. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache 49(1), 117-125 (2009).
225. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ 322(7277), 19-22 (2001).
226. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G: Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA 289(1), 65-69 (2003).
227. Charles JA, Jotkowitz S, Byrd LH: Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache 46(3), 503-507 (2006).
228. Gales BJ, Bailey EK, Reed AN, Gales MA: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann. Pharmacother. 44(2), 360-366 (2010).
229. Ba'albaki H, Rapoport A: Mast cells activate the renin angiotensin system and contribute to migraine: A hypothesis. Headache 48(10), 1499-1505 (2008).